R&D channel feed – Endpoints News

R&D channel feed

After positive panel vote, Shionogi antibiotic scores US approval

6 years ago

What does $62B buy you these days? A lot, says Takeda execs as the pharma player promises a blockbuster R&D future

6 years ago

Shorts galore: Muddy Waters sees slide for PeptiDream, tweets concerns about FibroGen's new data

6 years ago

Pincer movement: California biotech gets $35M to suffocate cancer in coordinated attack

6 years ago

Little biotech’s stock flatlines as its followup attempt at a depression drug trial win ends in another defeat

6 years ago

AstraZeneca, Merck win red carpet treatment at the FDA as a 3-time loser seeks speedy OK for rare tumors

6 years ago

FDA panel largely opposes expanding use of Lilly, Boehringer's SGLT2 inhibitor to type 1 diabetics

6 years ago

Bayer bets up to $100M on exploring new biomolecular condensate terrain with a biotech upstart

6 years ago

FDA slaps a hold on an AML trial as Marker scraps a failing ovarian cancer program, sinking shares

6 years ago

GSK's asthma biologic Nucala scores in rare blood disorder study

6 years ago

Eli Lilly-backed biotech grabs $100M to dispatch antibody-oligonucleotide conjugates after muscular dystrophy

6 years ago

Merck buys a fledgling neurodegenerative biotech spawned by an old GSK discovery alliance. What’s up with that?

6 years ago

AstraZeneca sets stage for marketing application with promising pivotal lupus drug data

6 years ago

Kiadis abandons lead PhIII program, shifts focus to natural killer cells

6 years ago

Editas and Celgene sub Juno are tackling hottest immunotherapy cells

6 years ago

Celgene execs shell out $92M cash for a pair of R&D deals that will fit perfectly in their new home at Bristol-Myers

6 years ago

Reata's bardoxolone offers promise in patients with rare kidney disorder

6 years ago

FDA Vascepa review spotlights new safety signals, possible mineral oil spoiler as Amarin hunts a blockbuster approval

6 years ago

Kadmon waxes rhapsodic on cGVHD results as race with Jakafi heats up

6 years ago

ARCH-backed Chinese biotech scores PhIII win for glucokinase-modulating diabetes drug

6 years ago

FDA puts Solid Bio’s lead gene therapy program on hold — again — after another patient is hurt by SGT-001

6 years ago

Safety qualms in MyoKardia mid-stage study cause investors to pause

6 years ago

Breakthrough status and promise of a speedy review arrives for Opdivo/Yervoy combination as Bristol-Myers bites at Bayer

6 years ago

Third time unlucky: Lipocine's latest quest to market their oral testosterone drug snubbed again by FDA

6 years ago

First page Previous page 223 224 225226227 228 229 Next page Last page